Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Change in Cash (2016 - 2022)

Edesa Biotech's Change in Cash history spans 10 years, with the latest figure at -$5.7 million for Q3 2022.

  • For Q3 2022, Change in Cash fell 2580.45% year-over-year to -$5.7 million; the TTM value through Sep 2022 reached -$748340.0, down 219.63%, while the annual FY2025 figure was $9.8 million, 325.59% up from the prior year.
  • Change in Cash for Q3 2022 was -$5.7 million at Edesa Biotech, down from -$3.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $10.0 million in Q1 2022 and bottomed at -$5.7 million in Q3 2022.
  • The 5-year median for Change in Cash is -$985382.5 (2018), against an average of $144272.0.
  • The largest annual shift saw Change in Cash soared 382.01% in 2019 before it plummeted 2580.45% in 2022.
  • A 5-year view of Change in Cash shows it stood at -$363132.0 in 2018, then crashed by 231.43% to -$1.2 million in 2019, then grew by 24.52% to -$908402.0 in 2020, then plummeted by 115.6% to -$2.0 million in 2021, then plummeted by 191.95% to -$5.7 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Change in Cash are -$5.7 million (Q3 2022), -$3.1 million (Q2 2022), and $10.0 million (Q1 2022).